[go: up one dir, main page]

RU2000110741A - Parenteral Administration Composition Containing Carbamazepine Or Its Derivatives - Google Patents

Parenteral Administration Composition Containing Carbamazepine Or Its Derivatives

Info

Publication number
RU2000110741A
RU2000110741A RU2000110741/14A RU2000110741A RU2000110741A RU 2000110741 A RU2000110741 A RU 2000110741A RU 2000110741/14 A RU2000110741/14 A RU 2000110741/14A RU 2000110741 A RU2000110741 A RU 2000110741A RU 2000110741 A RU2000110741 A RU 2000110741A
Authority
RU
Russia
Prior art keywords
parenteral composition
water
dibenz
azepine
carboxamide
Prior art date
Application number
RU2000110741/14A
Other languages
Russian (ru)
Other versions
RU2242231C2 (en
Inventor
ВАН-ХОГЕВЕСТ Петер
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9721497.7A external-priority patent/GB9721497D0/en
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2000110741A publication Critical patent/RU2000110741A/en
Application granted granted Critical
Publication of RU2242231C2 publication Critical patent/RU2242231C2/en

Links

Claims (10)

1. Парентеральная композиция, включающая 5Н-дибенз(b, f)азепин-5-карбоксамид и воду или растворитель на водной основе, причем композиция не содержит никаких других солюбилизирующих добавок.1. A parenteral composition comprising 5H-dibenz (b, f) azepine-5-carboxamide and a water or water-based solvent, wherein the composition does not contain any other solubilizing additives. 2. Парентеральная композиция, включающая 5Н-дибенз(b, f)азепин-5-карбоксамид, воду или растворитель на водной основе и глюкозу. 2. A parenteral composition comprising 5H-dibenz (b, f) azepine-5-carboxamide, water or an aqueous solvent and glucose. 3. Парентеральная композиция, включающая 10-гидрокси-10,11-тетрагидрокарбамазепин и воду. 3. A parenteral composition comprising 10-hydroxy-10,11-tetrahydrocarbamazepine and water. 4. Парентеральная композиция по п. 3, дополнительно включающая обеспечивающий изотоничность агент. 4. The parenteral composition according to claim 3, further comprising an isotonic agent. 5. Парентеральная композиция по п. 3 или 4, где обеспечивающий изотоничность агент представляет собой глюкозу. 5. The parenteral composition of claim 3 or 4, wherein the isotonicity agent is glucose. 6. Парентеральная композиция по пп. 2 и 5, в которой глюкоза присутствует в количестве 4,75 мас. % в пересчете на общую массу этой парентеральной композиции. 6. The parenteral composition according to paragraphs. 2 and 5, in which glucose is present in an amount of 4.75 wt. % in terms of the total weight of this parenteral composition. 7. Стандартная дозируемая форма, содержащая эффективное количество 5Н-дибенз(b, f)азепин-5-карбоксамида и воду или растворитель на водной основе, причем эта стандартная дозируемая форма не содержит никаких других солюбилизирующих добавок. 7. A unit dosage form containing an effective amount of 5H-dibenz (b, f) azepine-5-carboxamide and water or an aqueous solvent, and this unit dosage form does not contain any other solubilizing additives. 8. Контейнер, имеющий объем заполнения примерно 100 - 250 мл и заполненный раствором, содержащим терапевтически эффективное количество 5Н-дибенз(b, f)азепин-5-карбоксамида. 8. A container having a filling volume of about 100 to 250 ml and filled with a solution containing a therapeutically effective amount of 5H-dibenz (b, f) azepine-5-carboxamide. 9. Способ лечения эпилепсии у пациента, включающий введение парентеральной композиции по любому из предыдущих пунктов. 9. A method of treating epilepsy in a patient, comprising administering a parenteral composition according to any one of the preceding paragraphs. 10. Применение парентеральной композиции по любому из предыдущих пунктов для лечения эпилепсии. 10. The use of a parenteral composition according to any one of the preceding paragraphs for the treatment of epilepsy.
RU2000110741/15A 1997-10-09 1998-10-07 Parenteral composition for treatment of epilepsy RU2242231C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9721497.7A GB9721497D0 (en) 1997-10-09 1997-10-09 Organic compounds
GB9721497.7 1997-10-09

Publications (2)

Publication Number Publication Date
RU2000110741A true RU2000110741A (en) 2002-02-27
RU2242231C2 RU2242231C2 (en) 2004-12-20

Family

ID=10820342

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000110741/15A RU2242231C2 (en) 1997-10-09 1998-10-07 Parenteral composition for treatment of epilepsy

Country Status (31)

Country Link
US (2) US6316417B1 (en)
EP (1) EP1033988B1 (en)
JP (2) JP2001519395A (en)
KR (1) KR100760326B1 (en)
CN (1) CN1210032C (en)
AR (1) AR015465A1 (en)
AT (1) ATE257383T1 (en)
AU (1) AU748034B2 (en)
BR (1) BR9812861A (en)
CA (1) CA2304661C (en)
CO (2) CO5090854A1 (en)
CZ (1) CZ298900B6 (en)
DE (1) DE69821024T2 (en)
DK (1) DK1033988T3 (en)
ES (1) ES2214738T3 (en)
GB (1) GB9721497D0 (en)
HU (1) HU226106B1 (en)
ID (1) ID24134A (en)
IL (1) IL135123A0 (en)
MY (1) MY122129A (en)
NO (1) NO327263B1 (en)
NZ (1) NZ503526A (en)
PE (1) PE121998A1 (en)
PL (1) PL192287B1 (en)
PT (1) PT1033988E (en)
RU (1) RU2242231C2 (en)
SK (1) SK286253B6 (en)
TR (1) TR200000870T2 (en)
TW (1) TW584563B (en)
WO (1) WO1999018966A1 (en)
ZA (1) ZA989183B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
WO2007041524A2 (en) * 2005-09-30 2007-04-12 Ovation Pharmaceuticals, Inc. Novel parenteral carbamazepine formulation
JP5528708B2 (en) * 2006-02-09 2014-06-25 参天製薬株式会社 Stable formulations and methods for preparing and using them
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
CN101711739B (en) * 2008-10-08 2012-07-04 中国人民解放军军事医学科学院毒物药物研究所 Oral medicament combination of carbamazepine
CN105726466A (en) * 2014-12-10 2016-07-06 辽宁药联制药有限公司 Oxcarbazepine injection and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
EP0435826A1 (en) * 1989-12-27 1991-07-03 Ciba-Geigy Ag Intravenous solutions for epilepsy
DK0435825T3 (en) * 1989-12-27 1996-02-12 Ciba Geigy Ag Apparatus for homogenizing the inhomogeneous light distribution in a laser beam light beam
US5284662A (en) * 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
RU2020972C1 (en) * 1991-02-07 1994-10-15 Мегдятов Рашид Салехович Method for treating trifacial neuralgia
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine
FR2702148B1 (en) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application of anti-convulsants in the treatment of neuro-AIDS.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US5466683A (en) * 1994-08-25 1995-11-14 Teva Pharmaceutical Industries Ltd. Water-soluble analogs of carbamazepine

Similar Documents

Publication Publication Date Title
RU2203653C2 (en) Using n-propargyl-1-aminoindane r-enantiomer, its salts and compositions comprising thereof
RU97104030A (en) PHARMACEUTALLY STABLE DRUG OF OXALIPLATIN
RU93053497A (en) NEW PEPTIDES-AGONISTS AND THEIR USE
ES2029769A6 (en) Pharmaceutical compositions comprising sulfur containing carboxylic acids as the active agent as well as their use for combatting retroviruses.
CO5261582A1 (en) VALDECOXIB COMPOSITIONS
RU96119781A (en) APPLICATION OF 2-Phenyl-3-aroylbenzothiophenes to reduce the level of cholesterol in the serum, pharmaceutical composition
EA200101005A1 (en) HIGHLY EFFICIENT COMPOSITIONS CONTAINING DIHYDROERGOTAMINE
NZ239558A (en) Pharmaceutical compositions containing perfluorinated hydrocarbons and silicones as liquid carriers
CA2270286A1 (en) Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device
KR960700061A (en) PHARMACEUTICAL COMPOSITION FOR TREATING NICOTINE DEPENDENCE
RU2000110741A (en) Parenteral Administration Composition Containing Carbamazepine Or Its Derivatives
RU94034109A (en) AGENT FOR THE TREATMENT OF THE STATE OF ALARM
RU2002119210A (en) Oxcarbazepine Suspension
CA2270955A1 (en) Pharmaceutical composition containing morphinan derivative for treating drug dependence
KR950703527A (en) Prostaglandin derivatives
RU96109524A (en) COMPOSITION - MEDICINAL FORM OF ANTI-ARTISTIC MEANS OF GLUCOSAMINE HYDROCHLORIDE FOR INJECTION
KR920019350A (en) Pharmaceutical Compositions for Autoimmune Disease Therapy
KR960034200A (en) Anti-migraine indolylalkyl-pyridinyl and pyrimidinylpiperazine 1,2,5-thiadiazole derivatives
RU2000129666A (en) STABLE MITOXANTRON SOLUTIONS
RU97101109A (en) APPLICATION OF GABAPENTIN FOR TREATMENT OF FEAR AND PANIC CONDITIONS
KR950010896A (en) Composition for the prevention and treatment of myopia
KR880004810A (en) Peptic Ulcer Treatment
BE1006872A6 (en) Nasal pharmaceutical preparations with di-hydro-ergotamine (DHE)
KR980002033A (en) Triazole derivatives or salts thereof
BE1007420A3 (en) BULBS AND ACID SOLUTION INFUSION Thioctic FORM OF SALT WATER SOLUBLE ACID Thioctic.